Across TCGA pan-cancer cohorts, LINC01682 RNA is linked to patient survival in 9 of 34 cancer types, making it the most broadly survival-associated LINC01682 data layer.
The strongest signal is observed in uterine carcinosarcoma (UCS), where higher LINC01682 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated LINC01682 expression acts as an unfavorable survival marker, although some lineages such as LIHC show a favorable association.
UCS, CHOL, and BRCA are the cancer types where LINC01682 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.